---
title: "KeyBanc reduces its price target on Hinge Health, Inc. (HNGE) to $55 and maintains an overweight rating"
description: "KeyBanc has reduced its price target on Hinge Health, Inc. (NYSE:HNGE) to $55 from $70 while maintaining an Overweight rating. This adjustment comes as Hinge Health is listed among the 11 Newly-Listed"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276525268.md"
published_at: "2026-02-22T03:17:16.000Z"
---

# KeyBanc reduces its price target on Hinge Health, Inc. (HNGE) to $55 and maintains an overweight rating

> KeyBanc has reduced its price target on Hinge Health, Inc. (NYSE:HNGE) to $55 from $70 while maintaining an Overweight rating. This adjustment comes as Hinge Health is listed among the 11 Newly-Listed NYSE Stocks to Buy Now. Additionally, Evercore ISI analyst Elizabeth Anderson has lowered the price target to $50 from $65.

Hinge Health, Inc. (NYSE:HNGE) is among the 11 Newly-Listed NYSE Stocks to Buy Now. On February 11, 2026, KeyBanc reduced its price target on Hinge Health, Inc. (NYSE:HNGE) to $55 from $70 and maintained an Overweight rating. That same day, Evercore ISI analyst Elizabeth Anderson lowered the price target to $50 from $65 while keeping \[…\]

### Related Stocks

- [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md)
- [HNGE.US - Hinge Health](https://longbridge.com/en/quote/HNGE.US.md)
- [IHF.US - iShares US Healthcare Providers](https://longbridge.com/en/quote/IHF.US.md)
- [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md)
- [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Street View: Medtronic's early-stage product cycle strength evident, analysts say | Medtronicexceeded Wall Street's Q3 profit and revenue expectations, driven by strong heart device demand, but maintained | [Link](https://longbridge.com/en/news/276231714.md) |
| Guardant Health, Inc. $GH Shares Acquired by Assetmark Inc. | Assetmark Inc. significantly increased its stake in Guardant Health, Inc. by 18,838.6% during Q3, owning 13,257 shares v | [Link](https://longbridge.com/en/news/276508335.md) |
| Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX) | Wedbush analyst maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $30.00.President's D | [Link](https://longbridge.com/en/news/276450995.md) |
| Bowen Hanes & Co. Inc. Buys Shares of 325,000 Arista Networks, Inc. $ANET | Bowen Hanes & Co. Inc. acquired 325,000 shares of Arista Networks, Inc. (NYSE:ANET) in Q3, valued at approximately $47.3 | [Link](https://longbridge.com/en/news/276531578.md) |
| Forecasting The Future: 15 Analyst Projections For Humana | In the latest quarter, 15 analysts provided mixed ratings for Humana (NYSE:HUM), with an average 12-month price target o | [Link](https://longbridge.com/en/news/276258083.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.